Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Recruiting 4Active not recruiting 4Withdrawn 2Completed 2

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

CNS 2

Conditions

Carcinoma, Non-Small-Cell Lung 7Lung Neoplasms 4Colorectal Neoplasms 3Carcinoma, Hepatocellular 3Prostatic Neoplasms 2Neoplasm Metastasis 2Liver Neoplasms 2Glioblastoma 2Carcinoma, Renal Cell 2Breast Neoplasms 2Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Triple Negative Breast Neoplasms 1Thoracic Neoplasms 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Solid Tumors 1Select Advanced Solid Tumors 1Sarcoma 1Recurrence 1Prostate Adenocarcinoma 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Mesothelioma, Malignant 1Mesothelioma 1Melanoma 1Lymphoma, Non-Hodgkin 1Glioma 1Fallopian Tube Neoplasms 1Esophageal Neoplasms 1

Interventions

Temozolomide 9Magnetic Resonance Spectroscopy 9Bevacizumab 8Radiotherapy 4Radiation 4Lomustine 3Carmustine 3pembrolizumab 2dexamethasone acetate 2atezolizumab 2TIC10 compound 2Surgical Procedures, Operative 2Sunitinib 2Standard of Care 2Specimen Handling 2Sorafenib 2Radiosurgery 2Irinotecan 2Dexamethasone 2Carboplatin 2Calcium Dobesilate 2Axitinib 2Aminolevulinic Acid 2vocimagene amiretrorepvec 1tandutinib 1poly ICLC 1pazopanib 1niraparib 1keyhole-limpet hemocyanin 1gallium Ga 68 dotatate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Withdrawn × Glioblastoma × atezolizumab × Clear all
NCT06328036 2024-12-30

Testing the Combination of Anti-cancer Drugs Tiragolumab and Atezolizumab to Improve Outcomes for Patients With Recurrent Glioblastoma

National Cancer Institute (NCI)

Phase 2 Withdrawn
CNS

Glioblastoma

NCT03973879 2020-02-11

Combination of PVSRIPO and Atezolizumab for Adults With Recurrent Malignant Glioma

Duke University

Phase 1/2 Withdrawn
CNS

Brain Neoplasms, Glioblastoma, Glioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡